GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

GRAIL’s CFO Aaron Freidin said the Galleri multi-cancer early detection test delivered strong first-half growth, supported by expanded distribution via digital health platforms, employers, and physician offices. The update suggests improving traction rather than any negative regulatory or financial shock.

Analysis

GRAIL’s CFO Aaron Freidin said the Galleri multi-cancer early detection test delivered strong first-half growth, supported by expanded distribution via digital health platforms, employers, and physician offices. The update suggests improving traction rather than any negative regulatory or financial shock.